The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial. — SPRINT  

Non-small Cell Lung Cancer, NSCLC Clinical Trial

Official title: The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

Status Active, not recruiting

Clinical Trial Summary

The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than standard treatment, which is a combination of chemotherapy and radiotherapy.

Clinical Trial Description

This is a Phase II trial evaluating the efficacy and safety of sequential pembrolizumab (200 mg every three weeks) and accelerated, dose-painted radiotherapy for patients with locally advanced NSCLC with PD-L1 expression ≥ 50%. Patients with PD-L1 expression < 50% will also be enrolled and treated with standard concurrent chemoradiotherapy to serve as a non-randomized comparison group. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-small Cell Lung Cancer, NSCLC

• NCT number: NCT03523702
• Study type: Interventional
• Source: Albert Einstein College of Medicine
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 30, 2018
• Completion date: November 18, 2026